Generated by AI
NanoViricides, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies using its proprietary nanoviricide platform. The company’s current work centers on creating broad-spectrum nanomedicine drugs designed to target and neutralize virus particles before they infect healthy cells. Its lead candidate, NV-387, is being developed for multiple viral infections, including respiratory viruses and other high-priority infectious diseases. NanoViricides also maintains additional antiviral programs addressing conditions such as herpes and other viral threats. The company combines drug discovery, development, and commercialization capabilities within a single business model, supporting its efforts across research, preclinical work, and clinical development. Headquartered in Shelton, Connecticut, NanoViricides occupies a niche position in the healthcare market as a developer of specialized antiviral treatments aimed at complex viral diseases.
Website1 Controls Drive
Shelton, CT, 06484
United States
The latest articles about NNVC.
Summary of Oct 20's posts. Generated by AI.
Summary of May 27's posts. Generated by AI.
SHELTON, CT / ACCESS Newswire / October 5, 2026 / , Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, herewith provides additional details on its Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus (BDBV) and other Ebola viruses in the Democratic Republic of Congo ("DRC").
Summary of May 27's posts. Generated by AI.
Investors talking about NNVC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.